IBRX
HealthcareImmunityBio, Inc.
$2.08
+$0.06 (+2.97%)
Jan 5, 2026
Price History (1Y)
Analysis
ImmunityBio, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $2.05 billion. The company operates on a large scale, employing 673 individuals and generating revenue of $82.56 million (TTM). Its industry classification places it among other biotechnology companies. The company's financial health is marked by significant losses, with a net income of -$348.616 million (TTM) and an EBITDA of -$244.947 million (TTM). Despite these losses, ImmunityBio maintains a substantial cash balance of $257.81 million while carrying debt worth $861.29 million. The company's margins are also notable, with a gross margin of 99.6% and operating margin of -173.5%. However, its return on assets stands at -36.9%. ImmunityBio's valuation metrics include a forward P/E ratio of -8.00 and an EV/EBITDA of -10.83. The company has experienced rapid revenue growth, with a year-over-year increase of 425.1%. Dividend information is not available, but the payout ratio is 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About ImmunityBio, Inc.
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $2.05B
- P/E Ratio
- N/A
- 52-Week High
- $4.27
- 52-Week Low
- $1.83
- Avg Volume
- 11.17M
- Beta
- -0.04
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 673